Showing 7461-7470 of 8649 results for "".
- Texan Eye Enters Partnership with Comprehensive EyeCare Partnershttps://modernod.com/news/texan-eye-enters-partnership-with-comprehensive-eyecare-partners/2479472/Comprehensive EyeCare Partners (CompEye), a vision care practice management organization, has announced a strategic partnership with Texan Eye, an ophthalmic practice in Central Texas with practices in Austin and Cedar Park. Terms of the deal were not disclosed. Texan Eye, led by su
- Glaucoma Devices’ Expanding Role to Drive Double-Digit Market Growthhttps://modernod.com/news/glaucoma-devices-expanding-role-to-drive-double-digit-market-growth/2479465/Glaucoma surgical devices will see increased use in all stages of disease and in stand-alone glaucoma procedures over the next 5 years, as companies commercialize more devices designed to meet these needs, according to a Market Scope report. Market Scope expects the glaucoma surgical devi
- Glaucoma Research Foundation Receives $1.5 Million Gift For Collaborative Vision Restoration Initiativehttps://modernod.com/news/glaucoma-research-foundation-receives-1-5-million-gift-for-collaborative-vision-restoration-initiative/2479460/Glaucoma Research Foundation announced the receipt of a $1.5 million matching gift from Steve and Michele Kirsch of Palo Alto, California. The gift will help fund the Foundation’s collaborat
- US Prepares for Wide Rollout of COVID-19 Boosters Next Monthhttps://modernod.com/news/us-prepares-for-wide-rollout-of-covid-19-boosters-next-month/2479458/US officials announced that health agencies in the country are preparing to widely distribute third doses of mRNA COVID-19 vaccines beginning the week of September 20, citing new data that point to waning protection over time. The move was unveiled in a statement signed by health leaders includin
- Metrovision Receives FDA Clearance for MonPackONE for Vision Electrophysiologyhttps://modernod.com/news/metrovision-receives-fda-clearance-for-monpackone-for-vision-electrophysiology/2479454/Metrovision has received FDA clearance for its MonPackONE Vision Monitor for vision electrophysiology applications, including ganzfeld flash ERG and VEP, pattern ERG and VEP, multifocal ERG and VEP, as well as sensory
- Journal Highlights Desirable PK/PD Profiles of THR-687 and THR-149https://modernod.com/news/journal-highlights-desirable-pk-pd-profiles-of-thr-687-and-thr-149/2479450/Oxurion NV announced the publication of two related papers in the Journal of Pharmacokinetics and Pharmacodynamics entitled “Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach.” These papers describe the pharmacoki
- Biden Urges Congress to let Medicare Negotiate Prescription Drug Priceshttps://modernod.com/news/biden-urges-congress-to-let-medicare-negotiate-prescription-drug-prices/2479448/President Joe Biden on Thursday called on the US Congress to include strict controls on prescription drug prices in part by giving Medicare the power to negotiate them, according to a FirstWord report. “For
- Oculus Receives FDA Clearance for the Myopia Masterhttps://modernod.com/news/fda-clearance-for-the-new-oculus-myopia-master/2479444/Oculus announced that it has received FDA 510(k) clearance for the Myopia Master, which combines axial length, refraction values, and the central corneal radii measurements. The quick, contactless measurement method for axial length is not influenced by the accommodation status of the eye
- Visus Therapeutics to Host First Capital Markets Day in New York Cityhttps://modernod.com/news/visus-therapeutics-to-host-first-capital-markets-day-in-new-york-city/2479439/Visus Therapeutics announced that the company will host its first Capital Markets Day for investors, analysts, and media on August 31, 2021, from 10 am to 2 pm ET at Convene, 530 Fifth Avenue in New York City. During the Capital Markets Day, members of Visus’ leadership team and leading ey
- Eyevensys Raises $12M in a Series B Plus Funding Roundhttps://modernod.com/news/eyevensys-raises-12m-in-a-series-b-plus-funding-round/2479435/Eyevensys announced it has raised $12 million in a Series B Plus funding round. Korea Investment Partners is leading the Series B Plus financing and existing investors will also join the round. The financing will support Eyevensys’ accelerated development of its EYS809 program for the tr